NasdaqGS:AGIOBiotechs
A Look At Agios Pharmaceuticals (AGIO) Valuation After AQVESME FDA Approval And Commercial Launch
Agios Pharmaceuticals (AGIO) stock is in focus after the recent FDA approval and U.S. commercial launch of AQVESME for thalassemia, alongside upcoming mitapivat regulatory steps in sickle cell disease and a stated path to profitability.
See our latest analysis for Agios Pharmaceuticals.
Despite the AQVESME launch and upcoming mitapivat milestones, Agios Pharmaceuticals' recent 1-month share price return of 9.23% comes after a 90-day share price decline of 34.33% and a 1-year total shareholder...